Last reviewed · How we verify
Immunomodulatory
Immunomodulatory is a Small molecule drug developed by Aljazeera Hospital. It is currently in Phase 2 development.
Immunomodulatory treatments have been studied for various conditions, including Immune Thrombocytopenia, Blood Coagulation Disorders, and Type 1 Diabetes, using interventions such as Sitagliptin, Danazol, and Maintenance Immunosuppressive Treatment. Immunotherapy, a form of immunomodulation, involves harnessing or modifying the immune system to prevent, control, or eliminate disease, often by enhancing or restoring immune responses.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Immunomodulatory |
|---|---|
| Sponsor | Aljazeera Hospital |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH (PHASE2, PHASE3)
- Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma (PHASE2)
- Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases (PHASE1, PHASE2)
- Probiotic (LGG) for Veterans With PTSD (PHASE2)
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
- Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunomodulatory CI brief — competitive landscape report
- Immunomodulatory updates RSS · CI watch RSS
- Aljazeera Hospital portfolio CI
Frequently asked questions about Immunomodulatory
What is Immunomodulatory?
Who makes Immunomodulatory?
What development phase is Immunomodulatory in?
Related
- Manufacturer: Aljazeera Hospital — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing